Eli Lilly and Company $LLY Shares Sold by Wedbush Securities Inc.

Wedbush Securities Inc. lowered its position in shares of Eli Lilly and Company (NYSE:LLY) by 9.3% in the second quarter, HoldingsChannel.com reports. The fund owned 15,913 shares of the company’s stock after selling 1,624 shares during the quarter. Wedbush Securities Inc.’s holdings in Eli Lilly and Company were worth $12,405,000 as of its most recent filing with the SEC.

Several other large investors have also added to or reduced their stakes in the company. Rovin Capital UT ADV lifted its holdings in shares of Eli Lilly and Company by 11.8% during the second quarter. Rovin Capital UT ADV now owns 397 shares of the company’s stock worth $309,000 after purchasing an additional 42 shares during the period. Harvest Portfolios Group Inc. raised its position in Eli Lilly and Company by 28.3% during the 2nd quarter. Harvest Portfolios Group Inc. now owns 161,867 shares of the company’s stock worth $126,180,000 after buying an additional 35,712 shares during the last quarter. Aspect Partners LLC raised its position in Eli Lilly and Company by 263.2% during the 2nd quarter. Aspect Partners LLC now owns 345 shares of the company’s stock worth $269,000 after buying an additional 250 shares during the last quarter. RPS Advisory Solutions LLC lifted its stake in Eli Lilly and Company by 13.8% during the 2nd quarter. RPS Advisory Solutions LLC now owns 1,161 shares of the company’s stock valued at $905,000 after acquiring an additional 141 shares during the period. Finally, Sterling Capital Management LLC boosted its holdings in shares of Eli Lilly and Company by 18.3% in the 2nd quarter. Sterling Capital Management LLC now owns 51,748 shares of the company’s stock valued at $40,339,000 after acquiring an additional 8,016 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on LLY shares. HSBC raised their target price on shares of Eli Lilly and Company from $700.00 to $800.00 in a report on Wednesday, October 1st. Hsbc Global Res raised Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 27th. Deutsche Bank Aktiengesellschaft lowered their target price on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a research note on Monday, August 11th. Leerink Partners reissued a “market perform” rating and issued a $715.00 price target on shares of Eli Lilly and Company in a report on Thursday, August 7th. Finally, The Goldman Sachs Group raised their price objective on shares of Eli Lilly and Company from $876.00 to $879.00 and gave the stock a “buy” rating in a research note on Friday, October 10th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $960.88.

Insider Activity at Eli Lilly and Company

In other news, CEO David A. Ricks acquired 1,632 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the purchase, the chief executive officer owned 546,601 shares in the company, valued at $352,431,926.77. This trade represents a 0.30% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Daniel Skovronsky bought 1,000 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average price of $634.40 per share, with a total value of $634,400.00. Following the completion of the transaction, the executive vice president directly owned 137,660 shares of the company’s stock, valued at approximately $87,331,504. The trade was a 0.73% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have acquired 4,314 shares of company stock worth $2,766,929 in the last ninety days. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $923.35 on Friday. The stock has a market capitalization of $872.92 billion, a price-to-earnings ratio of 60.35, a PEG ratio of 1.21 and a beta of 0.43. The stock has a 50-day moving average of $799.97 and a 200 day moving average of $775.76. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $955.46.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The business had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business’s revenue was up 53.9% compared to the same quarter last year. During the same period in the previous year, the business earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Sell-side analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be issued a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 29.35%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.